Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)10.85m
- Net income in EUR-26.42m
- Incorporated2002
- Employees138.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sensorion SA | 0.00 | -22.06m | 209.57m | 50.00 | -- | 3.92 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
Nanobiotix SA | 30.06m | -39.70m | 256.64m | 102.00 | -- | -- | -- | 8.54 | -1.10 | -1.10 | 0.814 | -0.0391 | 0.3912 | -- | 19.59 | 294,686.30 | -51.67 | -54.11 | -120.56 | -80.68 | -- | -- | -132.08 | -756.15 | -- | -1.98 | 1.04 | -- | -- | 203.88 | 30.40 | -- | -7.81 | -- |
Euroapi SA | 1.02bn | -189.70m | 280.60m | 3.67k | -- | 0.3018 | -- | 0.2754 | -2.01 | -2.01 | 10.73 | 9.78 | 0.6086 | 1.38 | 4.24 | 277,705.10 | -11.34 | -- | -15.93 | -- | 16.15 | -- | -18.63 | -- | 0.6573 | -- | 0.1955 | -- | 3.87 | -- | -1,164.67 | -- | -- | -- |
Carbios SA | 24.00k | -27.22m | 384.92m | 134.00 | -- | 1.64 | -- | 16,038.44 | -2.03 | -2.03 | 0.0017 | 13.92 | 0.0001 | -- | 0.7619 | 179.10 | -11.20 | -9.92 | -12.13 | -10.77 | -4,783.33 | -- | -113,433.30 | -3,365.22 | 9.43 | -23.97 | 0.1517 | -- | -65.71 | -53.32 | 1.86 | -- | 141.01 | -- |
Medincell SA | 10.85m | -26.42m | 417.46m | 138.00 | -- | -- | -- | 38.49 | -1.02 | -1.02 | 0.4086 | -0.8965 | 0.2605 | -- | 6.81 | 75,853.15 | -63.46 | -59.54 | -115.15 | -117.36 | 60.43 | 68.38 | -243.58 | -451.26 | -- | -4.29 | 1.69 | -- | 141.78 | 8.96 | -29.04 | -- | -2.87 | -- |
Valneva SE | 153.71m | -101.43m | 470.76m | 684.00 | -- | 3.66 | -- | 3.06 | -0.7343 | -0.7343 | 1.11 | 0.924 | 0.2843 | 2.54 | 4.69 | 224,726.60 | -18.76 | -15.39 | -31.44 | -25.06 | 34.37 | 35.94 | -65.99 | -34.95 | 1.37 | -3.57 | 0.6195 | -- | -57.46 | 6.34 | 29.21 | -- | 35.18 | -- |
Guerbet SA | 785.69m | 23.87m | 474.67m | 2.92k | 20.88 | 1.25 | 5.70 | 0.6042 | 1.80 | 1.80 | 62.15 | 29.97 | 0.7997 | 0.5983 | 5.80 | 269,071.90 | 2.26 | 1.40 | 2.96 | 1.86 | 78.01 | 76.02 | 2.82 | 1.82 | 1.21 | 5.62 | 0.5035 | 57.82 | 4.30 | -0.0993 | 158.05 | -12.61 | 5.23 | -10.07 |
Boiron SA | 493.25m | 35.83m | 601.81m | 2.81k | 16.62 | 1.51 | 10.87 | 1.22 | 2.06 | 2.06 | 28.41 | 22.67 | 0.715 | 1.40 | 5.26 | 175,533.10 | 4.92 | 4.59 | 6.16 | 5.76 | 72.60 | 74.02 | 6.88 | 6.80 | 1.50 | -- | 0.0338 | 53.86 | -7.67 | -3.98 | -19.80 | -9.01 | -17.68 | -1.42 |
Holder | Shares | % Held |
---|---|---|
Mirova SA (Investment Management)as of 30 Jun 2023 | 2.27m | 7.81% |
Syquant Capital SASas of 30 Jun 2023 | 692.33k | 2.38% |
Polar Capital LLPas of 29 Feb 2024 | 345.67k | 1.19% |
BFT Investment Managers SAas of 29 Feb 2024 | 279.85k | 0.96% |
Saint Olive Gestion SNCas of 29 Dec 2023 | 245.00k | 0.84% |
Mandarine Gestion SAas of 30 Jun 2023 | 235.30k | 0.81% |
Amundi Asset Management SA (Investment Management)as of 29 Feb 2024 | 153.95k | 0.53% |
SG 29 Haussmann SASUas of 24 Apr 2024 | 140.00k | 0.48% |
DNCA Finance SAas of 30 Jun 2021 | 138.65k | 0.48% |
Soci�t� G�n�rale Gestion SAas of 29 Feb 2024 | 129.05k | 0.44% |